论文部分内容阅读
继发于肺表面活性物质(PS)缺乏的呼吸衰竭是造成早产儿死亡的主要原因之一。PS治疗不仅能降低早产儿呼吸系统疾病的病死率,还可用于胎粪吸入综合征、肺炎/脓毒症、肺出血足月儿的治疗。现对包括早产儿应用PS的有效性,预防性及治疗性的PS应用,PS剂型、应用技巧,PS短期、长期疗效,除急性呼吸窘迫综合征外的呼吸系统疾病的PS应用,产前激素及持续呼吸道正压通气与PS的关系等的研究进展进行分析。
Respiratory failure secondary to pulmonary surfactant deficiency (PS) is one of the major causes of death in preterm infants. PS treatment not only reduces the mortality of respiratory diseases in preterm infants, but also for the treatment of meconium aspiration syndrome, pneumonia / sepsis and full-term pulmonary hemorrhage. Now including the effectiveness of the application of PS in preterm infants, prophylactic and therapeutic applications of PS, PS dosage forms, application skills, PS short-term, long-term efficacy, PS application of respiratory diseases other than acute respiratory distress syndrome, prenatal hormone And the relationship between continuous positive airway pressure and PS and other research advances were analyzed.